Last update at 2025-03-14T20:12:00Z
Why Is Biogen (BIIB) Up 1.1% Since Last Earnings Report?
Fri 14 Mar 25, 03:30 PMWhy Gilead Sciences, Inc. (GILD) is the Best Pharma Stock to Buy According to Hedge Funds
Thu 13 Mar 25, 05:07 PMGILD vs. VRTX: Which Stock Is the Better Value Option?
Thu 13 Mar 25, 03:40 PMGilead (GILD) Up 10.3% Since Last Earnings Report: Can It Continue?
Thu 13 Mar 25, 03:30 PMBiotech Stock Roundup: TSVT Up on BMY Deal, PTGX Up on Data & More
Thu 13 Mar 25, 12:58 PMGILD Data on Once-Yearly Lenacapavir for HIV Prevention Positive
Wed 12 Mar 25, 07:00 PMAnalyst Says Gilead Sciences (GILD) is a ‘Big Liquid’ Stock You Should Pay Attention To
Wed 12 Mar 25, 06:16 PMGilead Presents New HIV Treatment And Cure Research Data
Wed 12 Mar 25, 04:55 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 5814.00M | 8278.00M | 1669.00M | 5160.00M | 7799.00M |
| Minority interest | 26.00M | 24.00M | -34.00000M | -22.00000M | 5.00M |
| Net income | 4592.00M | 6225.00M | 89.00M | 5386.00M | 5455.00M |
| Selling general administrative | 5673.00M | 5246.00M | 5151.00M | 4381.00M | 4056.00M |
| Selling and marketing expenses | - | - | - | - | - |
| Gross profit | 21624.00M | 20704.00M | 20117.00M | 17774.00M | 17274.00M |
| Reconciled depreciation | 2103.00M | 2050.00M | 1480.00M | 1404.00M | 1429.00M |
| Ebit | 7330.00M | 7406.00M | 7029.00M | 4287.00M | 7447.00M |
| Ebitda | 10393.00M | 9456.00M | 8509.00M | 6155.00M | 8876.00M |
| Depreciation and amortization | 3063.00M | 2050.00M | 1480.00M | 1868.00M | 1429.00M |
| Non operating income net other | -581.00000M | -639.00000M | -1418.00000M | 1868.00M | 676.00M |
| Operating income | 7330.00M | 7406.00M | 7029.00M | 4287.00M | 8200.00M |
| Other operating expenses | 16307.00M | 17210.00M | 14762.00M | 18162.00M | 13927.00M |
| Interest expense | 935.00M | 1001.00M | 984.00M | 995.00M | 1077.00M |
| Tax provision | 1248.00M | 2077.00M | 1580.00M | -204.00000M | 2339.00M |
| Interest income | - | - | - | 227.00M | 964.00M |
| Net interest income | -935.00000M | -1001.00000M | -984.00000M | -995.00000M | -1077.00000M |
| Extraordinary items | - | - | - | - | -4.00000M |
| Non recurring | 3644.00M | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1248.00M | 2077.00M | 1580.00M | -204.00000M | 2339.00M |
| Total revenue | 27281.00M | 27305.00M | 24689.00M | 22449.00M | 22127.00M |
| Total operating expenses | 10650.00M | 10609.00M | 10190.00M | 13487.00M | 9074.00M |
| Cost of revenue | 5657.00M | 6601.00M | 4572.00M | 4675.00M | 4853.00M |
| Total other income expense net | -1516.00000M | 872.00M | -5360.00000M | 873.00M | 676.00M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 4566.00M | 6201.00M | 89.00M | 5364.00M | 5460.00M |
| Net income applicable to common shares | 4592.00M | 6225.00M | 123.00M | 5386.00M | 5455.00M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 62125.00M | 63171.00M | 67952.00M | 68407.00M | 61627.00M |
| Intangible assets | 26454.00M | 28894.00M | 33455.00M | 33126.00M | 13786.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2374.00M | 1774.00M | 2141.00M | 2013.00M | 1440.00M |
| Total liab | 39376.00M | 41962.00M | 46888.00M | 50186.00M | 38977.00M |
| Total stockholder equity | 22749.00M | 21209.00M | 21064.00M | 18221.00M | 22650.00M |
| Deferred long term liab | - | 2673.00M | 4356.00M | - | - |
| Other current liab | 11280.00M | 8059.00M | 9389.00M | 7796.00M | 6547.00M |
| Common stock | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Capital stock | 1.00M | 1.00M | 1.00M | 1.00M | 1.00M |
| Retained earnings | 16304.00M | 15687.00M | 16324.00M | 14381.00M | 19388.00M |
| Other liab | - | 7301.00M | 35278.00M | 9536.00M | 6498.00M |
| Good will | 8314.00M | 8314.00M | 8332.00M | 8108.00M | 4117.00M |
| Other assets | - | 1.00M | 5988.00M | 4799.00M | 3119.00M |
| Cash | 6085.00M | 5412.00M | 5338.00M | 5997.00M | 11631.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 11280.00M | 11237.00M | 11610.00M | 11397.00M | 9759.00M |
| Current deferred revenue | -2348.00000M | - | - | - | - |
| Net debt | 18902.00M | 19818.00M | 21357.00M | 25405.00M | 12962.00M |
| Short term debt | 1798.00M | 2273.00M | 1516.00M | 2757.00M | 2499.00M |
| Short long term debt | 1798.00M | 2273.00M | 1516.00M | 2757.00M | 2499.00M |
| Short long term debt total | 24987.00M | 25230.00M | 26695.00M | 31402.00M | 24593.00M |
| Other stockholder equity | -16332.00000M | 5519.00M | 4656.00M | 3899.00M | 3176.00M |
| Property plant equipment | - | 5475.00M | 5121.00M | 4967.00M | 4502.00M |
| Total current assets | 16454.00M | 15227.00M | 15056.00M | 15816.00M | 31489.00M |
| Long term investments | 1163.00M | 1245.00M | 1309.00M | 502.00M | 1488.00M |
| Net tangible assets | - | -15968.00000M | -20723.00000M | -23032.00000M | 4622.00M |
| Short term investments | 1179.00M | 973.00M | 1182.00M | 1411.00M | 12721.00M |
| Net receivables | 4660.00M | 4777.00M | 4493.00M | 4892.00M | 3582.00M |
| Long term debt | 23189.00M | 22957.00M | 25179.00M | 28645.00M | 22094.00M |
| Inventory | 3366.00M | 2820.00M | 2734.00M | 3014.00M | 2067.00M |
| Accounts payable | 550.00M | 905.00M | 705.00M | 844.00M | 713.00M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | -84.00000M | -31.00000M | -5.00000M | 19.00M | 125.00M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | 28.00M | 2.00M | 83.00M | -60.00000M | 85.00M |
| Additional paid in capital | 6500.00M | - | - | - | - |
| Common stock total equity | - | 1.00M | 1.00M | 1.00M | 1.00M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 15687.00M | 16324.00M | 14381.00M | 19388.00M |
| Treasury stock | 0.00000M | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 5586.00M | 4016.00M | 5988.00M | 6390.00M | 7733.00M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 45671.00M | 47944.00M | 52896.00M | 52591.00M | 30138.00M |
| Capital lease obligations | - | - | - | - | - |
| Long term debt total | - | 22957.00M | 25179.00M | 28645.00M | 22094.00M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -2466.00000M | -3131.00000M | 11948.00M | -2307.00000M | 15279.00M |
| Change to liabilities | -1117.00000M | 207.00M | -58.00000M | -178.00000M | -2012.00000M |
| Total cashflows from investing activities | -2466.00000M | -3131.00000M | -14615.00000M | -7817.00000M | 14355.00M |
| Net borrowings | -1500.00000M | -4750.00000M | 5684.00M | -2750.00000M | -6250.00000M |
| Total cash from financing activities | -6469.00000M | -8877.00000M | 770.00M | -7634.00000M | -12318.00000M |
| Change to operating activities | -705.00000M | 647.00M | 426.00M | -696.00000M | 389.00M |
| Net income | 4566.00M | 6201.00M | 89.00M | 5364.00M | 5460.00M |
| Change in cash | 74.00M | -659.00000M | -5634.00000M | -6309.00000M | 10352.00M |
| Begin period cash flow | 5338.00M | 5997.00M | 11631.00M | 17940.00M | 7588.00M |
| End period cash flow | 5412.00M | 5338.00M | 5997.00M | 11631.00M | 17940.00M |
| Total cash from operating activities | 9072.00M | 11384.00M | 8168.00M | 9144.00M | 8400.00M |
| Issuance of capital stock | 309.00M | 169.00M | 256.00M | 209.00M | 289.00M |
| Depreciation | 2103.00M | 2050.00M | 1480.00M | 1404.00M | 1429.00M |
| Other cashflows from investing activities | -1798.00000M | -3131.00000M | -25913.00000M | -4685.00000M | -190.00000M |
| Dividends paid | -3709.00000M | -3605.00000M | -3449.00000M | -3222.00000M | 2971.00M |
| Change to inventory | -310.00000M | 11.00M | -195.00000M | -95.00000M | -310.00000M |
| Change to account receivables | -406.00000M | 313.00M | -1171.00000M | -218.00000M | 480.00M |
| Sale purchase of stock | -1396.00000M | -546.00000M | -1583.00000M | -1749.00000M | -2900.00000M |
| Other cashflows from financing activities | -173.00000M | -145.00000M | 8046.00M | -122.00000M | -486.00000M |
| Change to netincome | 3509.00M | 11384.00M | 6535.00M | -478.00000M | 2010.00M |
| Capital expenditures | 728.00M | 579.00M | 650.00M | 825.00M | 924.00M |
| Change receivables | -406.00000M | 313.00M | -1171.00000M | -218.00000M | 480.00M |
| Cash flows other operating | 727.00M | 689.00M | 1488.00M | 3345.00M | 1343.00M |
| Exchange rate changes | - | - | - | - | -85.00000M |
| Cash and cash equivalents changes | 137.00M | -624.00000M | -5677.00000M | -6307.00000M | 10352.00M |
| Change in working capital | -1763.00000M | 489.00M | -1638.00000M | -798.00000M | -939.00000M |
| Stock based compensation | 637.00M | 635.00M | 643.00M | 636.00M | 845.00M |
| Other non cash items | 5081.00M | 2125.00M | 7808.00M | 4636.00M | 1316.00M |
| Free cash flow | 8344.00M | 10805.00M | 7518.00M | 8319.00M | 7476.00M |
Sector: Healthcare Industry: Drug Manufacturers - General
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| GILD Gilead Sciences Inc |
-1.12 0.99% | 111.44 | 182.69 | 9.64 | 3.13 | 3.72 | 3.78 | 9.78 |
| LLY Eli Lilly and Company |
11.83 1.48% | 813.48 | 78.14 | 31.95 | 16.34 | 45.83 | 16.65 | 54.36 |
| JNJ Johnson & Johnson |
-0.18 0.11% | 162.81 | 29.17 | 14.33 | 3.74 | 5.18 | 3.80 | 15.22 |
| ABBV AbbVie Inc |
0.22 0.10% | 211.77 | 61.52 | 14.86 | 5.62 | 51.62 | 6.76 | 20.58 |
| MRK Merck & Company Inc |
-0.14 0.15% | 94.57 | 59.83 | 12.33 | 4.50 | 6.47 | 4.94 | 23.79 |
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
333 Lakeside Drive, Foster City, CA, United States, 94404
| Name | Title | Year Born |
|---|---|---|
| Mr. Daniel P. O'Day | Chairman & CEO | 1964 |
| Mr. Andrew D. Dickinson | Exec. VP & CFO | 1970 |
| Ms. Johanna Mercier | Chief Commercial Officer | 1970 |
| Dr. Merdad V. Parsey M.D., Ph.D. | Chief Medical Officer | 1963 |
| Ms. Diane E. Wilfong | Sr. VP, Corp. Controller & Chief Accounting Officer | 1962 |
| Ms. Jacquie Ross C.F.A. | VP of Investor Relations | NA |
| Ms. Deborah H. Telman | Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. | 1965 |
| Ms. Jyoti K. Mehra | Exec. VP of HR | 1976 |
| Dr. Michael Quigley Ph.D. | Sr. VP of Research Biology | NA |
| Dr. Linda Slanec Higgins Ph.D. | Sr. VP & Head of External Innovation | 1962 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...